Dyne Succeeds in Duchenne Trial; Sets Sights on Myotonic Dystrophy Goals
Zeleciment Rostudirsen Development: Dyne Therapeutics is advancing its lead drug candidate, Zeleciment rostudirsen, for Duchenne muscular dystrophy (DMD) towards a BLA submission in Q2 2026, following positive results from the Phase 1/2 DELIVER trial that showed significant increases in dystrophin levels and sustained functional improvements.
Future Clinical Trials: The company plans to initiate a global Phase 3 clinical trial for Zeleciment rostudirsen concurrently with the BLA submission, aiming for U.S. pharmacy availability by Q1 2027, pending FDA Priority Review.
Zeleciment Basivarsen Progress: Dyne is also developing Zeleciment basivarsen for Myotonic Dystrophy Type 1, with a BLA submission anticipated in early Q3 2027, following the completion of patient enrollment in the ongoing ACHIEVE trial.
Financial Position: As of September 30, 2025, Dyne Therapeutics reported $791.9 million in cash and marketable securities and has initiated a $300 million public offering to bolster its financial resources for pipeline development.
Trade with 70% Backtested Accuracy
Analyst Views on DYN
About DYN
About the author
Dyne Therapeutics Receives Orphan Drug Designation for z-basivarsen, ACHIEVE Trial Shows Sustained Improvement
- Clinical Trial Progress: Z-basivarsen demonstrates sustained functional improvement in the ACHIEVE trial, particularly in muscle strength and function, with enrollment for the registrational expansion cohort expected to complete in early Q2 2026, further advancing treatment options.
- Orphan Drug Designation: The MHLW in Japan has granted z-basivarsen orphan drug status for myotonic dystrophy type 1 (DM1), highlighting the urgent need for new therapies and potentially providing up to 10 years of market exclusivity if approved.
- Multiple Designations: Z-basivarsen has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, along with Orphan Drug designation from the EMA, indicating its development potential and market recognition on a global scale.
- Treatment Need: DM1 affects approximately 40,000 people in the U.S. and 55,000 in the EU, and the development of z-basivarsen aims to address the significant unmet medical need, carrying important social and economic implications.
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully closed an upsized public offering of 21,827,549 shares at $18.44 each, reflecting strong market demand for its therapeutic solutions and expected to provide substantial funding for future R&D initiatives.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs targeting muscle and central nervous system disorders, particularly myotonic dystrophy and Duchenne muscular dystrophy.
- Strong Underwriter Lineup: Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers, enhancing investor confidence in the offering due to their market influence and expertise.
- Effective Registration Statement: The offering was conducted under a shelf registration statement on Form S-3 filed on March 5, 2024, ensuring compliance and transparency, which is likely to bolster investor trust in the company's future growth prospects.
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully completed an upsized public offering of 21,827,549 shares at $18.44 per share, reflecting strong market confidence in its treatments for genetically driven neuromuscular diseases.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs, particularly for myotonic dystrophy and Duchenne muscular dystrophy, enhancing the company's therapeutic pipeline.
- Strong Underwriter Lineup: The involvement of Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities as joint book-running managers bolsters market trust and enhances Dyne's brand reputation in the biotech sector.
- Effective Registration Statement: The offering was conducted under an S-3 registration statement filed on March 5, 2024, ensuring compliance and streamlining the financing process, thereby increasing the company's flexibility in capital markets.
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results
Analyst Upgrade: Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform, raising the price target from $11 to $40 per share, citing positive data expectations from Avidity Biosciences' late-stage trial.
Market Reaction: Following Novartis' $12 billion acquisition of Avidity, Dyne's shares surged over 40%, indicating strong market confidence in Dyne's potential upside.
Future Expectations: Analyst Kostas Biliouris anticipates nearly 50% upside for DYN, driven by the expected Phase 3 readout in H2 2026 for Avidity's RNA therapy targeting myotonic dystrophy type 1.
Upcoming Catalysts: Biliouris expects Dyne's DM1 program for z-basivarsen to succeed, with potential catalysts including an FDA review of the company's Duchenne muscular dystrophy candidate.
Dyne Therapeutics Announces $350 Million Public Offering Pricing
Public Offering Announcement: Dyne Therapeutics (DYN) announced an upsized underwritten public offering of 19 million shares.
Pricing Details: The pricing details of the offering were disclosed late Tuesday.
Dyne Therapeutics Receives Orphan Drug Designation for z-basivarsen, ACHIEVE Trial Shows Sustained Improvement
- Clinical Trial Progress: Z-basivarsen demonstrates sustained functional improvement in the ACHIEVE trial, particularly in muscle strength and function, with enrollment for the registrational expansion cohort expected to complete in early Q2 2026, further advancing treatment options.
- Orphan Drug Designation: The MHLW in Japan has granted z-basivarsen orphan drug status for myotonic dystrophy type 1 (DM1), highlighting the urgent need for new therapies and potentially providing up to 10 years of market exclusivity if approved.
- Multiple Designations: Z-basivarsen has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, along with Orphan Drug designation from the EMA, indicating its development potential and market recognition on a global scale.
- Treatment Need: DM1 affects approximately 40,000 people in the U.S. and 55,000 in the EU, and the development of z-basivarsen aims to address the significant unmet medical need, carrying important social and economic implications.
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully closed an upsized public offering of 21,827,549 shares at $18.44 each, reflecting strong market demand for its therapeutic solutions and expected to provide substantial funding for future R&D initiatives.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs targeting muscle and central nervous system disorders, particularly myotonic dystrophy and Duchenne muscular dystrophy.
- Strong Underwriter Lineup: Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers, enhancing investor confidence in the offering due to their market influence and expertise.
- Effective Registration Statement: The offering was conducted under a shelf registration statement on Form S-3 filed on March 5, 2024, ensuring compliance and transparency, which is likely to bolster investor trust in the company's future growth prospects.
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
- Upsized Offering: Dyne Therapeutics successfully completed an upsized public offering of 21,827,549 shares at $18.44 per share, reflecting strong market confidence in its treatments for genetically driven neuromuscular diseases.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs, particularly for myotonic dystrophy and Duchenne muscular dystrophy, enhancing the company's therapeutic pipeline.
- Strong Underwriter Lineup: The involvement of Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities as joint book-running managers bolsters market trust and enhances Dyne's brand reputation in the biotech sector.
- Effective Registration Statement: The offering was conducted under an S-3 registration statement filed on March 5, 2024, ensuring compliance and streamlining the financing process, thereby increasing the company's flexibility in capital markets.
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results
Analyst Upgrade: Oppenheimer upgraded Dyne Therapeutics (DYN) to Outperform from Perform, raising the price target from $11 to $40 per share, citing positive data expectations from Avidity Biosciences' late-stage trial.
Market Reaction: Following Novartis' $12 billion acquisition of Avidity, Dyne's shares surged over 40%, indicating strong market confidence in Dyne's potential upside.
Future Expectations: Analyst Kostas Biliouris anticipates nearly 50% upside for DYN, driven by the expected Phase 3 readout in H2 2026 for Avidity's RNA therapy targeting myotonic dystrophy type 1.
Upcoming Catalysts: Biliouris expects Dyne's DM1 program for z-basivarsen to succeed, with potential catalysts including an FDA review of the company's Duchenne muscular dystrophy candidate.
Dyne Therapeutics Announces $350 Million Public Offering Pricing
Public Offering Announcement: Dyne Therapeutics (DYN) announced an upsized underwritten public offering of 19 million shares.
Pricing Details: The pricing details of the offering were disclosed late Tuesday.
